新加坡，2022年7月19日——药明康德今日宣布计划在新加坡建立研发和生产基地，并预计在未来十年累计投资20亿新元（约合14.3亿美元）用于新基地的建设，从而更好地为全球合作伙伴赋能，不断加速医药创新进程，造福全球病患。此项投资总额会根据公司业务发展需要，在未来10年内分阶段进行投入。 新基地的设立将会进一步拓展药明康德一体化赋能平台的能力和规模，计划建造先进的实验室和设施，为全球合作伙伴提供全方位的研发和生产服务。 未来，新加坡基地将进一步夯实药明康德的全球化运营网络，并与亚洲、欧洲、北美等地的基地联动，满足客户日益增长的需求，不断加强与全球合作伙伴的沟通协作。凭借其独特的CRDMO（合同研究、开发与生产）和CTDMO（合同测试、研发和生产）业务模式，药明康德可以更灵活地为客户提供高质量的服务，进一步赋能全球合作伙伴加速新药研发进程，为患者带来更多突破性的治疗方案。 新加坡经济发展局主席马宣仁医生表示：“药明康德通过此次投资计划将新加坡设为公司全球研发和生产网络的重要接口，我们对此表示热烈欢迎。这是对新加坡作为全球生物制药中心的认可，并将进一步提升我们对生物技术创新者和初创企业的吸引力。” “我们很期待能在新加坡设立研发和生产基地，并持续为当地的医药创新生态做出积极贡献。”药明康德董事长兼首席执行官李革博士表示：“这项投资计划将进一步拓展药明康德的能力和规模，更好地赋能全球合作伙伴加速医药创新，为患者谋福祉，早日实现‘让天下没有难做的药，难治的病’的伟大愿景。” 关于药明康德药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2021年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5800多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation SINGAPORE, July 19, 2022 – WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore. The company intends to invest up to S$2 billion (approximately US$1.43 billion) to construct and operationalize the site, which aims to further enable global partners to advance healthcare innovations. The investment is expected to be made in stages over the next 10 years, depending on the company’s business needs. The new site will further expand the capacity and enhance the capabilities of WuXi AppTec’s integrated enabling platform and will yield state-of-the-art laboratories and facilities that provide a broad portfolio of R&D and manufacturing services to customers worldwide. When completed, the Singapore site will serve a critical role in WuXi AppTec’s global network across Asia, Europe, and North America, meeting growing demand from multinational customers and strengthening collaborations with a wide range of partners. Together, and through their unique CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) business models, these facilities will provide a range of high-quality services with greater flexibility, allowing the company to better help partners worldwide advance drug discoveries and development and deliver groundbreaking treatments to patients in need. "We warmly welcome WuXi AppTec’s plan," said Dr. Beh Swan Gin, Chairman of the Singapore Economic Development Board (EDB). "The investment will establish Singapore as a significant node in the company’s global research, development and manufacturing network. It is a testament to Singapore’s position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups." "We are excited to establish this important presence for WuXi AppTec in Singapore and continue to contribute to the region’s dynamic life sciences ecosystem," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This investment will further enhance our capacity and capabilities so we can better support our collaborative partners globally and realize our shared vision that every drug can be made, and every disease can be treated." About WuXi AppTecAs a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,800 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com